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Abstract 
Objective: To evaluate the efficacy and safety of etanercept in a sample of Iraqi patients with ankylosing 
spondylitis patients. 
Patients and methods: A single center open labeled prospective study conducted on 74 patients with ankylosing 
spondylitis diagnosed according to modified New York criteria of ankylosing spondylitis. Patients received 
etanercept 25mg twice weekly and were assessed at baseline, at month1, 3, and 6 thereafter. Disease activity was 
evaluated by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and functional status by Bath 
Ankylosing Spondylitis Function Index (BASFI) at each visit. Safety assessments included adverse events and 
laboratory tests. 
Results: Mean age of patients was 35.2 ± 10 years, males represented 92% of the cases, and the mean disease 
duration was 9.29 ± 7.1 years. A significant decrease in BASFI and BASDAI was found after 1month,3 months, 
and 6 months compared to baseline( p<0.001). Multiple logistic regression analysis revealed no significant 
association between age of patients, disease duration, HLA-B27, family history of psoriasis or inflammatory 
bowel disease, nonsteroidal anti-inflammatory drugs intake, and duration of smoking with the changes in 
BASDAI and BASF of the patients. Drug related adverse effects included three patients developed injection site 
reaction, 10 patients upper respiratory tract infections, and no serious infections occurred Conclusion: 
Etanercept was effective and relatively safe in treatment of ankylosing spondylitis patients. Further investigation 
of longer term treatment with etanercept is warranted to further define its therapeutic utility. 
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1. Introduction 
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease characterized by inflammatory 
backpain, peripheral arthritis, enthesitis, and extraarticular features such as uveitis and inflammatory bowel 
disease(IBD) [Braun and Sieper , 2007].The disease has a relatively early onset, presenting at a mean age of 26 
years, and occurs somewhat more frequently in men than in women [Feldtkeller et al, 2003]. Disease progression 
may result in loss of mobility and function, and therefore patients can experience a heavy disease burden, with 
pain and stiffness, loss of physical function, and severe impairment in quality of life [Davis et al, 2005; Zink et 
al, 2000]. 
Therapeutic options for patients suffering from AS have been limited over the last decades. There is no 
evidence that disease modifying anti-rheumatic drugs (DMARDs) work in axial manifestations of 
[Roychowdhury et al, 2002;  Braun et al, 2006]. Tumour necrosis factor (TNF) blockers have greatly improved 
the condition of patients with active inflammatory spinal disease [Heiberg et al, 2005]. The short-term efficacy 
and safety of the recombinant 75-kd tumour necrosis factor (TNF) receptor IgG1 fusion protein etanercept 
(Enbrel) has been demonstrated in clinical studies of patients with active AS [Brandt  et al, 2003; Gorman  et al, 
2002; Davis  et al, 2004; Brandt  et al, 2005 ]. 
This study was designed to assess the efficacy and safety of etanercept in a sample of Iraqi patients with 
ankylosing spondylitis 
2. Patients and Methods 
2.1 Study design  
This was a single center, single group open labelled prospective study conducted at Rheumatology Unit in 
Baghdad Teaching Hospital from the 1st   of January to the 1st of August, 2013.Patients received etanercept 25 
mg twice weekly and evaluated at baseline and after 1month, 3 months, and 6 months for its efficacy and safety. 
Informed consent was obtained from all participants and this study was approved by the ethical committee of 
Baghdad University, College of Medicine -Medical Department. 
 
2.2 Sample selection 
Patients were included in the study if they had proved diagnosis of AS according to modified New York criteria 
of ankylosing spondylitis [Vander Linden et al, 1984] regardless the age or gender. Patients were excluded from 
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the study if they were currently on etanercept, refused to participate in the study, left the treatment or withdrew 
from the study, and those who developed serious complications. 
 
2.3 Clinical and laboratory evaluation 
Data were collected using a questionnaire form including age, gender, occupation, smoking habits, disease 
duration, medication used, and family history of psoriasis or IBD).  Efficacy measures were assessed at baseline 
of the study (Month 0) and at month 1,3, and 6 and included 0-100 scale assessments of Disease activity by 
using Bath ankylosing spondylitis disease activity index (BASDAI) [Garrett et al, 1994] and functional status 
using Bath ankylosing spondylitis functional index (BASFI) [Calin et al, 1994].  
  The safety of etanercept was assessed at each study visit in all patients who received at least one dose of 
study medication. Safety assessments included adverse events, premature discontinuations and laboratory tests 
were done for measuring hemoglobin (Hb), erythrocyte sedimentation rate(ESR), White blood cell count(WBC), 
liver function tests (ALT,AST) and renal function tests(Blood urea, serum creatinine).       
2.4 Statistical Analysis: 
Data of all patients were done using the statistical package for social sciences software for windows (SPSS v 18, 
Chicago, IL, USA).   Data were presented as mean and standard deviation for continuous variables: age, disease 
duration, BASDAI, BASFI and laboratory findings. Categorical variables were presented as numbers and 
percentages including gender, job, smoking, medication use, family history, and HLA-B27. Analysis of 
variances (ANOVA) test was used to compare the means of BASDAI, BASFI and laboratory findings and to 
assess the significance of changes in these variables at different time of follow up. Chi-square test (χ2) was used 
for testing the significance of differences in the categorical variables variable. . Findings with P value ≤ 0.05 
were considered significant. 
 
3. Results 
Of 75 AS patients enrolled in this study, 70 patients completed the study, three patients switched to another 
biological therapy (infliximab) and two patients lost follow up( figure 1). The baseline characteristics of them were 
shown in table 1. Mean age of the patients was 35.2 ± 10 years and mean disease duration was 9.29 ± 7.1 years. 
Sixty nine (92%) patients were males. More than one-third (34.7%) of the patients were current smokers, 3 (4%) 
patients were ex-smokers and 46 (61.3%) patients were never smokers. Positive HLA-B27 was present in 41 
(54.7%) studied AS patients, two patients (2.7%) had family history of IBD, and 60 (80%) patients were NSAIDs 
users. 
The Mean baseline BASDAI of the patients was 5.4 ± 0.24, after one month of weekly treatment with 
etanercept medication, mean BASDAI of the patients was 4.3 ± 0.20, after three months the mean BASDAI 
changed to 3.0 ± 0.19, reached to 2.2 ± 0.12 after six months. There was a significant decrease in BASDAI of the 
studied AS patients through the period of follow up of the patients after treatment with etanercept medication (p < 
0.001). Mean difference in BASDAI vs the baseline value was 1.1after one month, 2.4 after 3 months and 3.2 after 
6 months. The difference in BASDAI was highly significant (p < 0.001), indicating the good effect of etanercept, 
table 2.  
Mean baseline BASFI of the studied AS patients was 5.93 ± 0.23, decreased after one month to 5.1 ± 
0.21, after three months to 3.8 ± 0.20  and after six months it was 2.9 ± 0.10, with a highly significant decrease in 
BASFI as compared to baseline (p < 0.001). The mean difference in BASFI of the compared to baseline was 0.83 
after one month 2.13 after 3 months and after 6 month the mean difference in BASFI was 3.03, and this difference 
was significant at all times of follow up (p < 0.001), table 2. These findings indicate the effectiveness of etanercept 
in reduction of both disease activity and functional status.   
Multiple logistic regression analysis revealed no significant association between each of age of the 
patients, disease duration, HLA-B27, family history of psoriasis/IBD, NSAIDs intake and duration of smoking 
with changes in BASDAI, BASFI and functional class ( P>0.05) indicating that these changes were mainly due to 
the effect of etanercept ( table 3). 
Drug related adverse effects included three patients developed injection site reaction, 10 patients upper 
respiratory tract infections, and no serious infections occurred( Not shown in table). 
Finally, Etanercept effect on laboratory blood test of the patients showed significant reduction in WBC 
and ESR after 6 months of treatment (p< 0.001, Table 4).   
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                           Figure1: Flow chart of the study 
 
Table1. Baseline characteristics of   ankylosing spondylitis patients 
Variable         Value 
Age\ mean ± SD ( range) years 35.2 ± 10 (18 -59) 
Males n (%)  69 (92) 
Disease duration \  mean ± SD ( range) years 9.29 ± 7.1    
Smoking n (%) Current 26 (34.7) 
Ex-smoker 3 (4.0) 
Never 46 (61.3) 
Positive HLA-B27   n (%) 41 (54.7) 
Family History of   IBD     n (%) 2 (2.7) 
NSAIDs users      n (%) 60 (80) 
SD, standard deviation; IBD, inflammatory bowel disease; NSAIDs, nonsteroidal anti-inflammatory drugs 
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Table 2. Comparison in mean BASDAI and mean BASFI  at different follow up time. 
 
Variable Baseline 
(n=75) 
1 month 
(n=72) 
3 months 
(n=68) 
6 months 
(n=66) 
P 
BASDAI 5.4 ± 0.24 4.3 ± 0.20 3.0 ± 0.19 2.2 ± 0.12 <0.001* 
Mean difference  
from Baseline 
- 1.1 2.4 3.2 <0.001* 
BASFI 5.93 ± 0.23 5.1 ± 0.21 3.8 ± 0.20 2.9 ± 0.10 <0.001* 
Mean difference  
from Baseline 
- 0.83 2.13 3.03 <0.001* 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Function 
Index, * p<0.05 is significant. 
 
 
Table 3.  Multiple logistic regression analysis of patients' characteristics and response to treatment.  
 
Variable Standardized correlation 
coefficients 
t P 
Age -0.027- -0.092- 0.928 
Disease Duration 0.219 0.914 0.377 
HLA-B27 0.275 0.979 0.346 
Family history of psoriasis \IBD 0.457 1.686 0.116 
NSAIDs -0.068- -0.253- 0.804 
Duration of Smoking 0.406 1.253 0.232 
IBD, inflammatory bowel disease; NSAIDs, nonsteroidal anti-inflammatory drugs 
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Table 4. Effect of etanercept on laboratory blood tests  
 
Test Follow-up time P 
Baseline 
(n=75) 
1 month 
(n=72) 
3 months 
(n=68) 
6 months 
(n=66) 
Hb 13.2 13.3 13.4 13.2 0.85 
WBC x 1000 8.5 7.5 6.9 6.6 < 0.001 *  
ESR 31.2 19.86 18.19 16.12 < 0.001 * 
AST 22.1 22.9 21.7 20.1 0.49 
ALT 19.9 23.1 21.6 22.1 0.31 
Blood urea 33.8 33.2 31.8 32.2 0.40 
Serum 
Creatinine 
0.77 0.83 0.81 0.87 0.12 
Hb, haemoglobin; WBC, White blood cells; ESR, erythrocyte sedimentation rate; AST, aspartate transaminase; 
ALT, alanine transaminase.* P<0.05 is significant. 
 
4. Discussion 
AS is a chronic inflammatory disease often leading to permanent spinal damage, a considerable handicap, and a 
poor quality of life. Current treatments for AS are inadequate for most patients, especially treatments for axial 
skeletal involvement [Calin et al, 2004]. This study showed that etanercept 25mg twice weekly significantly 
reduced disease activity index and significantly improved the functional status of AS patients during the 6 months 
follow up period. 
 
Other studies have reported similar findings. Calin et al (2004)  conducted  a multicenter randomized 
double blind placebo controlled clinical trial in Europe, with 45 patients randomly assigned to etanercept 25 mg 
and 39 to placebo twice weekly for 12 weeks. They reported that scores on the BASDAI composite index and the 
BASDAI fatigue component improved 44% among etanercept patients (p=0.01 versus placebo) and had improved 
spinal flexion. In addition, a post hoc analysis of BASDAI responses showed that the percentage of etanercept 
patients with BASDAI scores, 40 increased from 9% at baseline to 71% at week12.    
Braun et al (2007) assessed the humanistic impact of AS and compared  the effect of etanercept 50 mg 
once-weekly,   etanercept 25 mg twice-weekly and placebo on patient-reported outcomes in a 12-week, double-
blind, placebo-controlled multicenter study conducted on  356 patients with active AS and reported significant 
improvement in BASFI and  significant reduction in BASDAI of etanercept groups compared to placebo. 
Another study in 2011 compared the efficacy and safety of etanercept with that of sulfasalazine after 16 
weeks of treatment in 379 patients with axial and peripheral manifestations of AS in a randomized, double-blind 
trial and demonstrated that etanercept was significantly more effective than sulfasalazine in improving the signs 
and symptoms of AS in the axial skeleton and peripheral joints [Braun et al, 2011]. 
A recent meta-analysis of randomized, double-blind, placebo-controlled clinical trials that included 1,570 
participants has investigated the efficacy of etanercept in Caucasian versus Chinese populations and reported that 
there was sufficient evidence to prove that etanercept has its advantages in both disease activity controlling and 
symptoms relieving, especially for axial joints compared with peripheral joints, without higher incidence of 
serious adverse events [Li et al, 2013]. 
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In this study, the non-significant association between age, disease duration, HLA-B27, family history of 
psoriasis/IBD, NSAIDs and duration of smoking with response to treatment on multiple regression analysis may 
indicate that the response was due to etanercept therapy.  
Notably, most laboratory findings were normal except leucocytes count which showed a significant 
decrease after 6 months of treatment with etanercept. Pancytopenia including leukopenia rarely has been reported. 
The causal relationship to etanercept therapy remains unclear. Although no high risk group has been identified, 
caution is recommended if the drug is to be used in patients with a previous history of significant hematologic 
abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and 
symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on 
etanercept and the drug should be discontinued if patient developed significant hematologic abnormalities [Sandhu 
et al, 2007]. 
The current study revealed a significant decline in ESR of AS patients after 6 months of treatment with 
etanercept. This in line with other studies which reported significant improvement in ESR after etanercept 
treatment [De Sanctis et al, 2013;  Bes et al, 2013].  ESR is an important measure for assessment of treatment of 
AS patients with peripheral arthritis in addition to strong correlation with BASDAI of AS patients [Heijde et al, 
2002]. 
Additionally, in this study, etanercept was well tolerated with an acceptable safety profile in adult patients 
with AS.  Drug related adverse effects included 10 patients upper respiratory tract infections, three patients 
developed injection site reaction,  two patients lost follow up and three switched to another biological therapy    
(infliximab) due to non-responsiveness, and no serious infections occurred. In the randomized clinical trials, the 
rate of adverse events was similar between the treatment and placebo groups, except for injection site reactions, 
which were more frequent in the etanercept groups [Davis et al, 2008; Dijkmans et al, 2009]. Another open-label 
extension study demonstrated that number of etanercept discontinuations because of adverse events was very low. 
Overall, serious adverse events occurred in less than 5% of the patients, and were often   unrelated to treatment 
[van der Heijde et al, 2009]. Recently an  open-label extension involving 59 AS patients treated with etanercept for 
264 weeks (original etanercept group) or 252 weeks (original placebo group) reported that  serious infections 
occurred at a rate of 0.03 events per subject years, while no cases of tuberculosis or opportunistic infections were 
reported [artín-Mola et al, 2010]. 
Limitations of this open label extension  study include  small sample size and short duration of follow up 
which  may solved by a larger and longer duration randomized prospective study. 
 
5. Conclusion 
 
Etanercept drug was effective and relatively safe in treatment of a sample of Iraqi patients with ankylosing 
spondylitis.  
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